Bullish
Lexicon Pharmaceuticals Inc. reported a Q1 2026 revenue of $21.1 million, a substantial increase from $1.3 million year-over-year, largely due to a $2...
Bullish
Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is highlighted as a fast-growing penny stock due to its significant Q1 2026 revenue increase to $21.1 mill...
Artal Participations S.a r.l., a major holder in LEXICON PHARMACEUTICALS, INC. (LXRX), reported an internal restructuring of its stake. The company co...
Artal Participations S.a r.l. and affiliated investment entities have updated their Schedule 13D filing for Lexicon Pharmaceuticals, Inc. The filing i...